Chemomab Therapeutics (NASDAQ:CMMB) Trading 1.9% Higher – Still a Buy?

by · The Cerbat Gem

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Get Free Report)’s share price traded up 1.9% on Friday . The company traded as high as $1.62 and last traded at $1.59. Approximately 34,203 shares changed hands during trading, a decline of 25% from the average daily volume of 45,326 shares. The stock had previously closed at $1.56.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Chemomab Therapeutics has a consensus rating of “Hold” and a consensus price target of $25.00.

Get Our Latest Research Report on CMMB

Chemomab Therapeutics Trading Up 1.9%

The stock has a market capitalization of $11.45 million, a P/E ratio of -0.72 and a beta of 0.62. The business has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.74.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18). On average, sell-side analysts predict that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 earnings per share for the current fiscal year.

Institutional Trading of Chemomab Therapeutics

Hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC bought a new position in shares of Chemomab Therapeutics in the 4th quarter valued at about $132,000. Kestra Private Wealth Services LLC increased its stake in Chemomab Therapeutics by 19.3% during the first quarter. Kestra Private Wealth Services LLC now owns 61,710 shares of the company’s stock worth $97,000 after acquiring an additional 10,000 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Chemomab Therapeutics during the fourth quarter valued at approximately $31,000. 46.05% of the stock is currently owned by hedge funds and other institutional investors.

Chemomab Therapeutics Company Profile

(Get Free Report)

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.

Featured Articles